|
|
|
||
|
|
||
|
||
| Title: | Allogeneic CD34+ Selected Peripheral Blood Cell Infusion Following Nonmyeloablative Chemotherapy in Patients with Multiple Myeloma |
|---|---|
|
|
| Phase: | I |
|
|
| Purpose: | To determine the lowest dose of chemotherapy necessary for successful engraftment of donor cells while decreasing the risk of graft vs host disease (GVHD) |
|
|
| Eligibility: |
|
|
|
| Treatment: | Patients receive 4 days of chemotherapy and then stem cell infusion. Patients can expect weekly clinic visits and immunosuppressive drugs for the first 60 to 90 days posttransplant. Then evaluations at 6 and 12 months with donor leukocyte infusion (DLI) if there is no GVHD. |
|
|
| Contact: |
Massachusetts Dana-Farber Cancer Institute Muriel Gannon 617-632-4597 |
 |
|
| Please note: the trials indicated do not include the full inclusion or exclusion criteria. For full protocols, please contact the Principal Investigator (PI) listed. |
|
|
|
|
|
|
Related Links
|